138 related articles for article (PubMed ID: 18691994)
1. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
3. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
Fousseyni T; Diawara M; Pasquier E; André N
J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
[TBL] [Abstract][Full Text] [Related]
4. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Twardowski PW; Smith-Powell L; Carroll M; VanBalgooy J; Ruel C; Frankel P; Synold TW
Cancer Invest; 2008 Feb; 26(1):53-9. PubMed ID: 18181046
[TBL] [Abstract][Full Text] [Related]
5. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
8. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study.
Mantadakis E; Herrera L; Leavey PJ; Bash RO; Winick NJ; Kamen BA
J Clin Oncol; 2000 Jul; 18(13):2576-81. PubMed ID: 10893289
[TBL] [Abstract][Full Text] [Related]
9. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
El Kababri M; Benmiloud S; Cherkaoui S; El Houdzi J; Maani K; Ansari N; Khoubila N; Kili A; El Khorassani M; Madani A; Tazi MA; Ahid S; Hessissen L; Quessar A; Harif M; Khattab M; André N
Pediatr Blood Cancer; 2020 Sep; 67(9):e28508. PubMed ID: 32658380
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
[TBL] [Abstract][Full Text] [Related]
11. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Sterba J; Valik D; Mudry P; Kepak T; Pavelka Z; Bajciova V; Zitterbart K; Kadlecova V; Mazanek P
Onkologie; 2006 Jul; 29(7):308-13. PubMed ID: 16874014
[TBL] [Abstract][Full Text] [Related]
12. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
Perroud HA; Rico MJ; Alasino CM; Queralt F; Mainetti LE; Pezzotto SM; Rozados VR; Scharovsky OG
Future Oncol; 2013 Mar; 9(3):451-62. PubMed ID: 23469980
[TBL] [Abstract][Full Text] [Related]
13. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.
Khan OA; Blann AD; Payne MJ; Middleton MR; Protheroe AS; Talbot DC; Taylor M; Kirichek O; Han C; Patil M; Harris AL
Br J Cancer; 2011 Jun; 104(12):1822-7. PubMed ID: 21587257
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.
Traore F; Togo B; Pasquier E; Dembélé A; André N
Indian J Cancer; 2013; 50(3):250-3. PubMed ID: 24061467
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis.
Rome A; André N; Scavarda D; Gentet JC; De Paula AM; Padovani L; Pasquier E
Pediatr Blood Cancer; 2009 Aug; 53(2):246-7. PubMed ID: 19441112
[No Abstract] [Full Text] [Related]
16. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
White L; McCowage G; Kannourakis G; Nayanar V; Colnan L; Kellie S; Shaw P; Seshadri R; Lockwood L; Tiedemann K
J Clin Oncol; 1994 Mar; 12(3):522-31. PubMed ID: 8120550
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
18. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
Mainetti LE; Rozados VR; Rossa A; Bonfil RD; Scharovsky OG
J Cancer Res Clin Oncol; 2011 Jan; 137(1):151-63. PubMed ID: 20349084
[TBL] [Abstract][Full Text] [Related]
19. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
20. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
